BioCentury
ARTICLE | Clinical News

AdreView regulatory update

September 22, 2008 7:00 AM UTC

FDA approved an NDA from General Electric's GE Healthcare unit for AdreView as a molecular imaging agent to detect neuroendocrine tumors. The company plans to launch the iobenguane I 123 injection, wh...